research research research-lab cancer-center m true

Maus Lab

The goal of the Maus lab is to design and evaluate next generation genetically-modified (CAR) T cells as immunotherapy in patients with cancer.
Marcela V. Maus, MD, PhD
Marcela V. Maus, MD, PhD

Explore the Maus Lab

Research Summary

Using the immune system as a cancer treatment has the potential to induce long-term, durable remissions, and perhaps even cure some patients. The T cells of the immune system are able to specifically kill the target cells they recognize. T cells are also able to persist in the body for many years, and form immune ‘memory,’ which enables the possibility of long-term protection. The Maus laboratory is interested in using genetic engineering techniques to re-direct T cells to find and kill tumor cells, while sparing healthy tissues. We aim to develop new ways to design molecular receptors to target T cells to liquid and solid tumors; use T cells as delivery vehicles for other drugs, and use drugs to help T cells work against tumors; and understand how T cells can work as “living drugs” to treat patients with cancer.

Research Projects

Immune therapies that engage T cells have the potential to induce long-term durable remissions of cancer. In hematologic malignancies, allogeneic hematopoietic stem cell transplant can be curative, in part due to T-cell mediated anti-tumor immunity. In solid tumors, checkpoint blockades with anti- CTLA-4 or anti-PD-1 monoclonal antibodies can mediate long-term responses by releasing T cells from tightly controlled peripheral tolerance. Our laboratory focuses on T cell biology and T cell engineering. Chimeric antigen receptors (CARs) are synthetic molecules designed to re-direct T cells to specific antigens. Re-directing T cells with CARs is an alternative method of overcoming tolerance, and has shown great promise in the clinical setting for B cell malignancies such leukemia and lymphoma. However, successful application of this form of therapy to other cancers is likely to require refinements in the molecular and clinical technologies.

The goal of the Maus lab is to design and evaluate next generation genetically-modified T cells as immunotherapy in patients with cancer.

Specifically, the engineered T cells that the Maus lab are intended to overcome specific obstacles observed in the clinic. The next generation T cells will:

  1. Contain molecular designs to enhance specificity, potency, and safety.
    Most chimeric antigen receptors used to re-direct T cells to a new target are based on a canonical structure of murine single-chain antibody fragments fused to a costimulation domain and CD3zeta. Novel types of antigen receptors are in development and could be exploited to re-direct T cells such that they can distinguish between antigen expressed on the tumor and the same antigen expressed in healthy tissues. In liquid tumors, it will also be important to improve the safety of CAR T cells, while in solid tumors, the focus is on increasing their potency.
  2. Are administered in combination with other drugs to sensitize tumors to T cell mediated killing and/or potentiate T cell function.
    Many of the small molecule drugs and antibodies in clinical exert their effects on signaling pathways in tumor cells, T cells, and other immune cells. We aim to discover synergistic drug/T cell combinations to increase safety and efficacy, and use genetic engineering tools to confer specific drug sensitivity, resistance, or enhanced molecular switches.
  3. Have additional modifications that make CAR T cells (a) resistant to inhibitory mechanisms, (b) imageable, or (c) more feasible to manufacture and administer.
    Control of T cell function is a complex process orchestrated by a variety of molecules, some of which deliver inhibitory signals. Tumors often express ligands to inhibit T cell function. Using a single vector, genetically modified T cells can be re-directed not only to recognize a new antigen on tumor cells, but also to be resistant to the inhibitory tumor micro-environment.
  4. We aim to understand the basic biology and mechanisms that drive natural and engineered T cell functions.
    The Mass General Cellular Immunotherapy Program directed by Dr. Maus aims to generate a pipeline of genetically engineered CAR T cells to use as “living drugs” in patients with cancer. The program is composed of a “research and discovery” arm, “a regulatory/translational” arm to be able to test genetically-modified T cells in human subjects, and a “reverse translation” arm that consists of immune profiling to examine the engraftment, persistence, and bioactivity of T cell products infused into patients. The Immune Monitoring Laboratory is directed by Dr. Kathleen Gallagher.

Publications

Selected Publications

Boroughs AC, Larson RC, Marjanovic ND, Gosik K, Castano AP, Porter CBM, Lorrey SJ, Ashenberg O, Jerby L, Hofree M, Smith-Rosario G, Morris R, Gould J, Riley LS, Berger TR, Riesenfeld SJ, Rozenblatt-Rosen O, Choi BD, Regev A, Maus MV. A Distinct Transcriptional Program in Human CAR T Cells Bearing the 4-1BB Signaling Domain Revealed by scRNA-Seq. Mol Ther. 2020 Jul 25:S1525-0016(20)30374-9.

Schmidts A, Ormhøj M, Choi BD, Taylor AO, Bouffard AA, Scarfò I, Larson RC, Frigault MJ, Gallagher K, Castano AP, Riley LS, Cabral ML, Boroughs AC, Velasco Cárdenas RM, Schamel W, Zhou J, Mackay S, Tai YT, Anderson KC, Maus MV. Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma. Blood Adv. 2019 Nov 12;3(21):3248-3260.

Ormhøj M, Scarfò I, Cabral ML, Bailey SR, Lorrey SJ, Bouffard AA, Castano AP, Larson RC, Riley LS, Schmidts A, Choi BD, Andersen RS, Cédile O, Nyvold CG, Christensen JH, Gjerstorff MF, Ditzel HJ, Weinstock DM, Barington T, Frigault MJ, Maus MV. Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19. Clin Cancer Res. 2019 Dec 1;25(23):7046-7057.

Choi BD, Yu X, Castano AP, Bouffard AA, Schmidts A, Larson RC, Bailey SR, Boroughs AC, Frigault MJ, Leick MB, Scarfò I, Cetrulo CL, Demehri S, Nahed BV, Cahill DP, Wakimoto H, Curry WT, Carter BS, Maus MV. CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. Nat Biotechnol. 2019 Sep;37(9):1049-1058.

Frigault MJ, Dietrich J, Martinez-Lage M, Leick M, Choi BD, DeFilipp Z, Chen YB, Abramson J, Crombie J, Armand P, Nayak L, Panzini C, Riley LS, Gallagher K, Maus MVTisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. Blood. 2019 Sep 12;134(11):860-866.

Boroughs AC, Larson RC, Choi BD, Bouffard AA, Riley LS, Schiferle E, Kulkarni AS, Cetrulo CL, Ting D, Blazar BR, Demehri S, Maus MV. Chimeric antigen receptor costimulation domains modulate human regulatory T cell function. JCI Insight, March 2019.

Research Image


Potentiating Novel Engineered Cellular Therapies for Solid Tumors



Maus Lab


Group Members

  • Stefanie Bailey, PhD
  • Trisha Berger, PhD
  • Gabrielle Brini
  • Amanda Bouffard
  • Diane Brunett
  • Kathleen Gallagher, PhD
  • Korneel Grauwet, PhD
  • Lu Huang, PhD
  • Max Jan, MD, PhD
  • Tamina Kienka**
  • Michael Kann
  • Rebecca Larson*
  • Mark Leick, MD
  • Joseph Lombardi
  • Irene Scarfo, PhD
  • Andrea Schmidts, MD
  • Emily Silva. MS
  • Harrison Silva
  • Sonika Vatsa
  • Marc Wehrli, MD, PhD
  • Jennifer Yam

* PhD Candidate
**MD Candidate